Acquisitions of biotech companies with development-stage drug candidates often include earnout agreements.  The buyer pays the seller’s stockholders with cash or stock upfront, and the seller’s stockholders are entitled to additional payments if the drug or drugs in development reach certain milestones, often culminating in FDA approval or commercialization.  Achieving those milestones can take many…